Zinger Key Points
- Anat Ashkenazi resigns as CFO, Gordon Brooks appointed interim CFO effective July 15, 2024.
- : Eli Lilly's stock shows resilience despite concerns over patient withdrawals from Ozempic
- Get two weeks of free access to pro-level trading tools, including news alerts, scanners, and real-time market insights.
Shares of Eli Lilly And Company LLY announced that its Chief Financial Officer, Anat Ashkenazi, has resigned to pursue a new career. Gordon Brooks has been appointed as the interim CFO, effective July 15 2024. The company is actively searching for a permanent replacement.
What Else: Additionally, Eli Lilly’s shares are being closely watched due to a circulating article highlighting a high number of patients quitting Ozempic, a weight loss drug, due to severe side effects. This issue has impacted the broader market sentiment around weight loss medications, with lawsuits alleging severe side effects like stomach paralysis and blindness according to DailyMail.
LLY Price Action: Eli Lilly and Company shares were slightly up, trading 0.80% higher at $940.00 at the time of writing, according to Benzinga pro.
See Also: Spotify’s Long-Term Growth and Pricing Power Set to Boost Revenue: Analyst
Photo by rafapress on Shutterstock.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
